USE OF IMMUNE CONTENT SCORES DIAGNOSTICALLY TO PREDICT RESPONSIVENESS OF PROSTATE CANCER PATIENTS TO IMMUNOTHERAPY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 26, 2024
app pub date -
Jan 13, 2022
filing date -
Jan 15, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present disclosure pertains to the field of personalized medicine and methods for treating prostate cancer. In particular, the disclosure relates to the use of immune content scores to identify individuals in need of treatment for prostate cancer who are likely to be responsive to immunotherapy. The disclosure further relates to methods and immune content scores that identify tumors with enhanced immune activity and are prognostic for metastasis-free and disease-free survival for cancer patients.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully